November 2023 - TinyGems

WednesdayNov 22, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer

Genprex was granted orphan drug designation by the FDA earlier this year for development of REQORSA combined with Tecentriq in small cell lung cancer Use of REQORSA combined with Tecentriq is the subject of Genprex’s upcoming Acclaim-3 clinical trial Genprex took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted event, a Virtual Key Opinion Leaders on Bringing Gene Therapy to the Fight Against Lung Cancers Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was…

MondayNov 20, 2023 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Generate Sizable License Revenue from IP Growth, Expanding Patent Suite

Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as affirmed by clinical testing This overall effectiveness and push for its development has earned Lexaria 37 granted patents globally, with many patents pending The company is constantly enhancing its patent portfolio, since granted patents can support an increase in licensing revenue Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property…

ThursdayNov 16, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) CEO Underscores Commitment to Continued Growth in Letter to Shareholders

Fr8Tech CEO recently wrote a letter to shareholders summarizing the company’s financial milestones and operational successes CEO Javier Selgas discussed the company’s robust revenue growth in Q2 2023 as well as the 93% year-over-year increase in its gross margins during the first half of the year The company’s commitment to innovation has led to the launch of an LTL offering and the establishment of an AI department Fr8Tech has successfully expanded into new markets, completed a number of strategic integrations with third-party solutions, and grown its customer base Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company whose lead product is…

TuesdayNov 14, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for potential diabetes and weight loss treatment The company hopes to make these drugs more effective with reduced side effects, and even more accessible to people living with diabetes The move is aimed to help the company partner with the behemoths in an industry projected to bring in between $150 billion and $200 billion a year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is evaluating the impact of its patented DehydraTECH(TM) technology…

FridayNov 10, 2023 9:00 am

Renovaro Biosciences Inc. (NASDAQ: RENB) CEO Provides Update on Combination with AI Expert GEDiCube Intl Ltd. in Letter to Shareholders

The agreement with GEDiCube rebrands the company as a wholly-owned subsidiary under the name Renovaro.AI The combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights, and targeted immunotherapies, for cancer and other diseases The AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the largely untapped precision medicine market In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced a definitive agreement…

ThursdayNov 09, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Secures Request for Quotation with Global Pharmaceutical Conglomerate for Secure Product Transport

Freight Technologies announced securing a Request for Quotation from a leading global pharmaceutical giant that awards the company 33 lanes of transport pharmaceutical goods from the United States to Canada and Mexico The Request for Quotation extends over seven months, and Fr8App will provide uninterrupted, end-to-end logistics solutions, including secure transport, tracking, and reporting for each load The company’s dedicated team of professionals will oversee this vital operation to guarantee the smooth and efficient delivery of the pharmaceutical company’s critical products Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process through…

WednesdayNov 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Patented DehydraTECH(TM) Technology’s Effectiveness on GLP-1 Drugs for Potential Diabetes Treatment and Weight Loss

Lexaria, a global innovator in drug delivery platforms, recently announced plans to launch new human and animal studies examining whether its patented DehydraTECH(TM) technology can make GLP-1 drugs better Lexaria has previously demonstrated DehydraTECH’s overall potential in its DIAB-A22-1 animal study, which yielded weight loss, and improved triglyceride and cholesterol levels among diabetic-conditioned animals The company plans to replicate the results from this study while also exploring ways to improve the overall bioavailability of GLP-1 drugs for diabetes treatment and weight loss Lexaria management is optimistic that it will build on previous studies, replicate previous positive results, and improve the…

MondayNov 06, 2023 9:00 am

Renovaro Biosciences Inc. (NASDAQ: RENB) Announces Three New Members to Board of Directors as Definitive Agreement with GEDiCube Announced

Renovaro added Avram Miller, Leni Boeren, Ruud Hendriks, to the company's board of directors The three additions bring extensive financial backgrounds that will help as the company ventures into the new agreement with GEDiCube and Renovaro AI branding Avram Miller believes that Renovaro Bioscience, combined with GEDiCube, has the key elements to play a significant role in transforming AI's impact on medicine Renovaro Biosciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, recently announced a definitive agreement to combine with the advanced AI Company GEDiCube Intl Ltd., rebranding…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Month: November 2023